Sacubitril/valsartan vs Enalapril in acute heart failure - Video

Published On 2022-08-17T09:15:41+05:30 | Updated On 13 Oct 2023 3:24 PM IST

Overview

A recent study compared the safety and efficacy of valsartan/sacubitril (angiotensin receptor neprilysin inhibitor [ARNI]) against enalapril (angiotensin-converting enzyme inhibitor [ACEI]) in patients with acute heart failure at 6-month follow-up. The study is published in Indian Heart Journal.

The study was a prospective, single centre, and observational study where patients with acute decompensated heart failure with reduced ejection fraction were included. Patients were divided in two groups: valsartan/sacubitril (ARNI) group and enalapril (ACEI). Patients were followed up for at least 6 months after administration of first dose and were evaluated for safety, efficacy, and tolerability of target drug.

A total of 200 patients were included in the present study,100 each in angiotensin receptor neprilysin inhibitor and angiotensin-converting enzyme inhibitor group. The mean maximum tolerated dose by population in angiotensin receptor neprilysin inhibitor group was 203.6 mg and 8.9 mg in angiotensin-converting enzyme inhibitor group. Re- admission for heart failure were seen significantly higher in angiotensin-converting enzyme inhibitor group than angiotensin receptor neprilysin inhibitor group. Parameters like ejection fraction, left ventricular end diastolic and systolic dimensions, 6 min walk test and Kansas City Cardiomyopathy Questionnaires (KCCQ) were also looked into.

Therefore, the researchers concluded that the angiotensin receptor neprilysin inhibitor study group showed better safety and efficacy outcomes at the end of 6 months follow-up compared to angiotensin-converting enzyme inhibitor group.

Reference:

Tahir Saleem Bhat, Imran Hafeez, Sobia Fatima Tak, "Safety and efficacy of ARNI (valsartan/sacubitril) vs ACEI (enalapril) in acute heart failure e A prospective observational study" ;https://doi.org/10.1016/j.ihj.2022.04.003.

Speakers

Dr. Nandita Mohan

BDS, MDS( Pedodontics and Preventive Dentistry)

Dr. Nandita Mohan is a practicing pediatric dentist with more than 5 years of clinical work experience. Along with this, she is equally interested in keeping herself up to date about the latest developments in the field of medicine and dentistry which is the driving force for her to be in association with Medical Dialogues. She also has her name attached with many publications; both national and international. She has pursued her BDS from Rajiv Gandhi University of Health Sciences, Bangalore and later went to enter her dream specialty (MDS) in the Department of Pedodontics and Preventive Dentistry from Pt. B.D. Sharma University of Health Sciences. Through all the years of experience, her core interest in learning something new has never stopped. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751

Dr. Kamal Kant Kohli

Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751